
Roberto Carmagnani Pestana

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2941663/publications.pdf Version: 2024-02-01



Roberto Carmagnani

#	Article	IF	CITATIONS
1	Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies. Ca-A Cancer Journal for Clinicians, 2022, 72, 165-182.	329.8	132
2	IL-6–Mediated Induction of Matrix Metalloproteinase-9 Is Modulated by JAK-Dependent IL-10 Expression in Macrophages. Journal of Immunology, 2014, 192, 349-357.	0.8	110
3	Hepatocellular Carcinoma Immunotherapy. Annual Review of Medicine, 2022, 73, 267-278.	12.2	86
4	Histology-agnostic drug development — considering issues beyond the tissue. Nature Reviews Clinical Oncology, 2020, 17, 555-568.	27.6	60
5	Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA. Clinical Cancer Research, 2019, 25, 6107-6118.	7.0	54
6	Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma. Cancer Immunology Research, 2019, 7, 1390-1395.	3.4	54
7	Impact of antibiotic use on survival in patients with advanced cancers treated on immune checkpoint inhibitor phase I clinical trials. Annals of Oncology, 2018, 29, 2396-2398.	1.2	52
8	Prognostic Factors in Patients with Metastatic Breast Cancer with Bone-Only Metastases. Oncologist, 2018, 23, 1282-1288.	3.7	46
9	Response rates and survival to systemic therapy after immune checkpoint inhibitor failure in recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncology, 2020, 101, 104523.	1.5	38
10	Immunotherapy response evaluation with magnetic resonance elastography (MRE) in advanced HCC. , 2019, 7, 329.		33
11	Moving Beyond 3+3: The Future of Clinical Trial Design. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, e133-e144.	3.8	33
12	Origin and role of hepatic myofibroblasts in hepatocellular carcinoma. Oncotarget, 2020, 11, 1186-1201.	1.8	27
13	Unique Aberrations in Intimal Sarcoma Identified by Next-Generation Sequencing as Potential Therapy Targets. Cancers, 2019, 11, 1283.	3.7	19
14	Clinical and prognostic significance of circulating levels of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma. Oncotarget, 2018, 9, 37721-37732.	1.8	16
15	Systemic Options for Malignant Peripheral Nerve Sheath Tumors. Current Treatment Options in Oncology, 2021, 22, 33.	3.0	16
16	Precision Oncology in Sarcomas: Divide and Conquer. JCO Precision Oncology, 2019, 3, 1-16.	3.0	14
17	Consequences of the Implementation of the Model for End-stage Liver Disease System for Liver Allocation in Brazil. Transplantation Proceedings, 2013, 45, 2111-2114.	0.6	12
18	Impact of tissue-agnostic approvals for patients with sarcoma. Trends in Cancer, 2022, 8, 135-144.	7.4	11

Roberto Carmagnani

#	Article	IF	CITATIONS
19	Basket Trials: Review of Current Practice and Innovations for Future Trials. Journal of Clinical Oncology, 2022, 40, 3520-3528.	1.6	10
20	Precision Medicine Targeting FGFR2 Genomic Alterations in Advanced Cholangiocarcinoma: Current State and Future Perspectives. Frontiers in Oncology, 2022, 12, 860453.	2.8	9
21	Response to Pembrolizumab in Advanced Anal Squamous Cell Carcinoma With High TMB and PD-L1 and PD-L2 Amplification. Clinical Colorectal Cancer, 2021, 20, 350-353.	2.3	5
22	Discovery of targeted expression data for novel antibody-based and chimeric antigen receptor-based therapeutics in soft tissue sarcomas using RNA-sequencing: clinical implications. Current Problems in Cancer, 2021, 45, 100794.	2.0	4
23	The face mask as an established symbol against COVID-19. Revista Da Associação Médica Brasileira, 2020, 66, 1318-1319.	0.7	3
24	Diagnostic difficulty in Peutz–Jeghers syndrome. Journal of Coloproctology, 2015, 35, 067-071.	0.1	2
25	Changes in the Care Setting of First Consults to Palliative and Supportive Care Over a Seven-Year Period. Journal of Pain and Symptom Management, 2019, 57, 86-92.	1.2	2
26	Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib. Oncotarget, 2021, 12, 756-766.	1.8	2
27	An Observational Study of Circulating Plasma and Serum Insulin-Like Growth Factor 1 as Prognostic Biomarkers in Surgical Hepatocellular Carcinoma Patients. Surgery, Gastroenterology and Oncology, 2019, 24, 73.	0.1	2
28	Budd-Chiari Syndrome after Bilateral Nephrectomy for Polycystic Kidney Disease in a Kidney Transplant Recipient. Urologia Internationalis, 2020, 104, 330-332.	1.3	0